Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPAL pharmacokinetic interaction study of boceprevir and raltegravir
NL-OMON36218Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of boceprevir and raltegravir in hepatitis C virus infection and human immunodeficiency virus infection (HIV), sponsored by Radboud University Medical Center. Primary endpoint: Raltegravir pharmacokinetics. Started Sep 2011; status: active, not recruiting.
02
Drugs
boceprevirraltegravir
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON36218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36218.